Related Experiment Video
Updated: Jul 17, 2026
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Clinical development of antiepileptic drugs for children
1University of Michigan School of Medicine, Ann Arbor, Michigan 48103, USA. Garfalo@umich.edu
Insights
Developing new antiepileptic drugs (AEDs) requires a pediatric clinical development plan. Special considerations for children, including ethical issues, dosing, and study design, are crucial for safe and effective treatments.
Area of Science:
- Pediatric pharmacology
- Clinical trial design
- Drug development
Background:
- Pediatric drug development legislation has evolved, emphasizing tailored clinical plans for new antiepileptic drugs (AEDs).
- Ethical considerations are paramount in pediatric study design and execution.
- Regulatory discussions have highlighted the need for specific pediatric drug development strategies.
Purpose of the Study:
- To outline the essential components of a clinical development plan for new antiepileptic drugs (AEDs) specifically for pediatric populations.
- To address the unique challenges and considerations in pediatric clinical trials for AEDs.
Main Methods:
- Review of existing pediatric drug development legislation and regulatory guidelines.
- Analysis of ethical considerations in pediatric clinical research.
- Discussion of pharmacokinetic studies and dosing strategies in children.
- Examination of age-specific efficacy endpoints and safety monitoring in pediatric AED trials.
Main Results:
- Clinical studies in children generally follow adult trials, with exceptions for rare pediatric seizure types.
- Formulation, dosing, and recruitment present unique challenges in pediatric populations.
- Efficacy extrapolation from adults is possible for some pediatric seizures but not for infants.
- Seizure counts are valid endpoints, potentially supplemented by EEG monitoring in younger children.
Conclusions:
- A dedicated pediatric clinical development plan is essential for new antiepileptic drugs.
- Pediatric trials require adjusted designs, considering age, seizure types, and ethical factors.
- Long-term safety monitoring in growing children is critical for antiepileptic drug development.
Abstract:
A clinical development plan specific to children is a necessary component of every development plan for a new antiepileptic drug (AED). In the last decade, considerable discussion has occurred in the medical and regulatory communities, resulting in specific pediatric drug development legislation. Ethical issues are a foremost consideration in the design and conduct of studies. The timing of clinical studies differs between adults and children. In general, studies in children will not be performed until efficacy and safety has been demonstrated in adults. Exceptions include development of AEDs for seizure types seen only in children. Formulation preparation and dosing selection are often more challenging in children. Clinical trials including pharmacokinetic studies will be conducted in patients. A relatively small number of children, given subdivision into age groups and seizure types, are available for study. Clinical trials must be designed with children in mind, adjusting the length of the trials and the choice of controls. Efficacy extrapolation from adults may be considered for partial seizures in children, but not in infants. Seizure counts remain an appropriate efficacy endpoint; however, ascertainment in infants and younger children may require EEG monitoring. Safety specific to growing and developing children must be evaluated and long-term effects monitored.
Related Concept Videos
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...